<DOC>
	<DOCNO>NCT00328367</DOCNO>
	<brief_summary>The purpose study determine whether aripiprazole augmentation safe effective treatment clozapine-treated patient refractory schizophrenia .</brief_summary>
	<brief_title>Aripiprazole Augmentation Clozapine-Treated Patients With Refractory Schizophrenia</brief_title>
	<detailed_description>Clozapine renowned efficacy treat schizophrenia refractory typical atypical antipsychotic . Though effectiveness clozapine establish , considerable number patient schizophrenia partially responsive unresponsive clozapine . In addition , long-term use clozapine associate development obsessive-compulsive symptom metabolic syndrome . In order overcome short-comings increase efficacy , aripiprazole augmentation implement . Quantitative electroencephalogram use monitor occurrence abnormal finding analyze change electroencephalographic pattern linear non-linear methodology . Comparisons : Design double-blind randomize placebo control study patient Refractory Schizophrenia Clinique Department Neuropsychiatry Seoul National University Hospital .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Male female patient , 1865 year age . Patients must diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) . Female patient menarche must use medically accept mean contraception ( e.g . oral contraceptive , DepoProvera , abstinence ) . Each patient must provide write informed consent full explanation study protocol , authorized legal guardian must understand nature study must also give assent study participation . Patients must baseline ( day 0 ) BPRS score least 35 2 5 SANS global rating item score least 3 . Patients receive clozapine treatment 1 year change clozapine dosage 3 month . Patients must history antipsychotic treatment least 2 different kind prior clozapine administration . Subjects fluent Korean . DSMIV substance ( except nicotine caffeine ) dependence within past 1 year . Female patient either pregnant lactating . Mental retardation ( IQ &lt; 70 ) . Neurological disorder include epilepsy , stroke , severe head trauma . Clinically significant laboratory abnormality , follow test : CBC differential , electrolytes , BUN , creatinine , hepatic transaminase , urinalysis EKG . Prior history aripiprazole nonresponse intolerance . BPRS score &lt; 35 4 5 SANS global rating item score &lt; 3 . Participation clinical trial another investigational drug within 3 month ( 90 day ) prior study entry . Treatment injectable depot neuroleptic within less three dose interval last depot neuroleptic injection baseline ( day 0 ) . History electroconvulsive therapy within past 3 month . Subjects fluent Korean .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>clozapine</keyword>
</DOC>